about
Future pharmacological treatments for substance use disordersAddiction science: Uncovering neurobiological complexityVesicular monoamine transporter 2: role as a novel target for drug developmentNorepinephrine and stimulant addictionNeurobiologic Advances from the Brain Disease Model of AddictionDopaminergic Regulation of Striatal Interneurons in Reward and Addiction: Focus on AlcoholStriatal cholinergic interneuron regulation and circuit effectsGlial modulators: a novel pharmacological approach to altering the behavioral effects of abused substancesNeural circuits and motivational processes for hungerMultiple roles for orexin/hypocretin in addictionDopamine D4 receptors in psychostimulant addictionOverlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptorsAgonist Medications for the Treatment of Cocaine Use DisorderGlutamatergic transmission in drug reward: implications for drug addictionActivation of reward circuitry in human opiate addictsThe neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humansDefunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporterInhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addictionAdenosine-cannabinoid receptor interactions. Implications for striatal functionAdenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted ratsMonoamine transporter inhibitors and substrates as treatments for stimulant abuseUpdate on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.A rodent "self-report" measure of methamphetamine craving? Rat ultrasonic vocalizations during methamphetamine self-administration, extinction, and reinstatementChanges in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuseBehavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.Galanin-induced decreases in nucleus accumbens/striatum excitatory postsynaptic potentials and morphine conditioned place preference require both galanin receptor 1 and galanin receptor 2.Striatocortical pathway dysfunction in addiction and obesity: differences and similaritiesNeuroimaging the Effectiveness of Substance Use Disorder Treatments.Colocalization of tyrosine hydroxylase and GAD65 mRNA in mesostriatal neurons.The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Blunted opiate modulation of prolactin response in smoking men and womenDesign, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intakeAn investigation of cigarettes smoking behavior and nicotine dependence among Chinese methamphetamine users in two provincesThe vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study.Effects of compounding drug-related stimuli: escalation of heroin self-administration.Addiction: beyond dopamine reward circuitry.Effects of psychotropic agents on extinction of lever-press avoidance in a rat model of anxiety vulnerability.
P2860
Q22242633-A2715C98-9DEE-4E0E-A258-EFF3848F6BF5Q22251251-2B647D38-0231-47C7-B74F-07504DF997DCQ24647764-144A19E8-4D8E-4134-A53F-67A9C8A4485AQ24656833-28F14CE3-B064-4E00-A29F-54609AF4DA70Q26774129-36298F05-B772-4AC4-B9CE-5553807362DBQ26798176-1CDAF53E-74A4-4784-9193-5685FA1CCCACQ26863113-166F7F07-FF6C-46DE-AB83-794E98A0463BQ27003932-CE0DECF8-8D9E-4737-B7AB-0AA2A05DF7D9Q27007132-553907BC-D671-411E-81DD-37142836080EQ27009536-A9C8B6B3-7D3E-433F-A6CB-383CED70F9B4Q27026759-E132AA8F-1F02-4D7D-B3B5-1812D02EDFB2Q27335194-2AB8664A-822B-4685-B15D-CC049B3D6A56Q28087404-D6D565BB-675E-4425-96E1-6C20E2857DD2Q28112161-46D2F322-5AD2-4513-AEE7-898C343F26ACQ28140274-5EE7862F-E7BC-4F12-89C9-446F366E6182Q28236333-B64ACA30-87EE-4CC4-AFA0-0BF891A9D662Q28267727-A1417D4F-A956-4757-A38E-139E7E101064Q28283718-74777F29-A1C7-4AFA-B3C3-73E03D2C7F91Q28286488-D8BE56B1-66F4-4980-BC0E-483937F216E9Q28566486-4D303155-2042-4E97-A026-F8460167EBDEQ30413718-A1CD71F3-ABB7-489B-862B-C58D2224A44DQ30440516-75DCB12A-41D5-4898-8D75-2E724E55EDDEQ30444980-CDDC83D2-91B9-41FC-8900-9DF5AAEFFBF0Q30484807-6870A019-1F33-4191-BC1F-B89F1D59FA4FQ30492329-C2E84043-C5A3-4656-9A1A-3B6E6F16B008Q30539653-20E7DF92-ED56-440B-9413-C5FB71C42FEBQ30578245-B75115CE-AFEB-4C0F-A0A1-3B1F321D8B7EQ31096451-336CFC00-DDF2-448F-B5CE-8B73F50A09FEQ31788807-C4D704FE-5654-4695-86F7-9D5194097817Q33598487-99E697CA-3537-476C-B299-E397FE702B6DQ33710038-E5F305EE-AB64-45A4-8F4C-13E5CBC9B59DQ33738102-573B8371-C5E0-4018-B92C-454B746900D4Q33757216-7F38426B-3CBC-4159-BF75-945874DC3AF2Q33787564-95B1FA5E-3B1B-4B80-8640-6218BB8ED7E6Q33849764-034A5F45-6AE9-48CB-B287-CBBFEE5FB7D1Q33854736-6BADF494-D12D-4DA5-8C0F-3177D2B5662CQ34068906-A2874E00-C53C-436F-B475-382AD1889A23Q34136425-6020C4A2-A5BC-4102-A409-63B64E490F3DQ34170714-4B20EC10-4FE0-4FC2-87F7-CE403A297A9AQ34180554-8AC44061-A802-4F5C-AEBC-DB4BF83EF88E
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Neural mechanisms of drug reinforcement.
@ast
Neural mechanisms of drug reinforcement.
@en
type
label
Neural mechanisms of drug reinforcement.
@ast
Neural mechanisms of drug reinforcement.
@en
prefLabel
Neural mechanisms of drug reinforcement.
@ast
Neural mechanisms of drug reinforcement.
@en
P1476
Neural mechanisms of drug reinforcement.
@en
P2093
P304
P356
10.1111/J.1749-6632.1992.TB25966.X
P407
P577
1992-06-01T00:00:00Z